Jan. 15, 2021
On Jan. 15, 2021, the Department of Defense (DoD), in
coordination with the Department of Health and Human Services (HHS),
awarded a $69.3 million contract to CONTINUUS Pharmaceuticals Inc. to
develop a domestic production capability for critical active
pharmaceutical ingredients (APIs) and final dosage form medicines using
their proprietary integrated continuous manufacturing (ICM) technology.
ICM enables rapid, on-demand production of medicines from API to final
dosage form without interruption in a fully-automated, small-footprint
facility.
This investment will enable CONTINUUS to commercialize its
small-footprint, end-to-end pharmaceutical manufacturing technology.
Critical APIs and their starting materials have long been sourced from
overseas and this collaboration will onshore the production of three
critical APIs and their final dosage forms. These medicines are
currently used to treat critically ill COVID-19 patients. CONTINUUS’
proprietary technology will also enable the establishment of a new
manufacturing logistics capability, allowing more efficient delivery of
medical countermeasures in future healthcare crises.
The DoD’s Defense Assisted Acquisition (DA2) Cell led this effort in coordination with HHS. This effort was funded through the Coronavirus Aid, Relief, and Economic Securities (CARES) Act, to support critical technology development.
Posts
No comments:
Post a Comment